Cue Biopharma (CUE)vsRevolution Medicines Inc (RVMD)
CUE
Cue Biopharma
$28.74
+2.64%
HEALTHCARE · Cap: $208.78M
RVMD
Revolution Medicines Inc
$205.11
+0.66%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Cue Biopharma generates 4975% more annual revenue ($37.66M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. CUE earns a higher WallStSmart Score of 27/100 (F).
CUE
Avoid27
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 166.7% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 65.3x book value
Trading at 16.9x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : CUE
The strongest argument for CUE centers on Revenue Growth. Revenue growth of 166.7% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : CUE
The primary concerns for CUE are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 3.81 is elevated, increasing financial risk.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
CUE profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
CUE carries more volatility with a beta of 2.46 — expect wider price swings.
CUE is growing revenue faster at 166.7% — sustainability is the question.
CUE generates stronger free cash flow (-29M), providing more financial flexibility.
Bottom Line
CUE scores higher overall (27/100 vs 24/100) and 166.7% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cue Biopharma
HEALTHCARE · BIOTECHNOLOGY · USA
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biological drugs for the selective modulation of the human immune system to treat a variety of cancers, chronic infectious diseases, and autoimmune disorders. The company is headquartered in Cambridge, Massachusetts.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?